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Abstract: 1-Deoxysphingolipids (deoxySLs) are atypical sphingolipids that are elevated in the plasma
of patients with type 2 diabetes and hereditary sensory and autonomic neuropathy type 1 (HSAN1).
Clinically, diabetic neuropathy and HSAN1 are very similar, suggesting the involvement of deoxySLs
in the pathology of both diseases. However, very little is known about the biology of these lipids and
the underlying pathomechanism. We synthesized an alkyne analog of 1-deoxysphinganine (doxSA), the
metabolic precursor of all deoxySLs, to trace the metabolism and localization of deoxySLs. Our results
indicate that the metabolism of these lipids is restricted to only some lipid species and that they are
not converted to canonical sphingolipids or fatty acids. Furthermore, exogenously added alkyne-doxSA
[(2S,3R)-2-aminooctadec-17-yn-3-ol] localized to mitochondria, causing mitochondrial fragmentation and
dysfunction. The induced mitochondrial toxicity was also shown for natural doxSA, but not for sphinga-
nine, and was rescued by inhibition of ceramide synthase activity. Our findings therefore indicate that
mitochondrial enrichment of an N-acylated doxSA metabolite may contribute to the neurotoxicity seen
in diabetic neuropathy and HSAN1. Hence, we provide a potential explanation for the characteristic
vulnerability of peripheral nerves to elevated levels of deoxySLs.
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instead of  canonical  sphinganine  (SA)  (1,  2).  Specific 
point mutations in SPT, which induce a pronounced shift 
in the preference of the enzyme toward l-alanine,  were 
found to be causal of the rare genetic peripheral neuropa-
thy hereditary sensory and autonomic neuropathy type 1 
(HSAN1) (2). This autosomal-dominant inherited disease 
is  characterized  by  slow  and  length-dependent  dying-back  
of  sensory  axons, with  variable damage  also  to motor  and 
Abstract 1-Deoxysphingolipids (deoxySLs) are atypical 
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type 2 diabetes and hereditary sensory and autonomic neu-
ropathy type 1 (HSAN1). Clinically, diabetic neuropathy and 
HSAN1 are very similar, suggesting the involvement of de-
oxySLs in the pathology of both diseases. However, very 
little is known about the biology of these lipids and the 
underlying pathomechanism. We synthesized an alkyne ana-
log of 1-deoxysphinganine (doxSA), the metabolic precursor 
of all deoxySLs, to trace the metabolism and localization of 
deoxySLs. Our results indicate that the metabolism of these 
lipids is restricted to only some lipid species and that they 
are not converted to canonical sphingolipids or fatty acids. 
Furthermore, exogenously added alkyne-doxSA [(2S,3R)-
2-aminooctadec-17-yn-3-ol] localized to mitochondria, caus-
ing mitochondrial fragmentation and dysfunction. The 
induced mitochondrial toxicity was also shown for natural 
doxSA, but not for sphinganine, and was rescued by inhibi-
tion of ceramide synthase activity.  Our findings therefore 
indicate that mitochondrial enrichment of an N-acylated 
doxSA metabolite may contribute to the neurotoxicity seen 
in diabetic neuropathy and HSAN1. Hence, we provide a po-
tential explanation for the characteristic vulnerability of pe-
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provide valuable insights into the biology of deoxySL-medi-
ated neurotoxicity? Our data  show  that deoxySLs cannot 




inducing changes in the organelle morphology such as 
swelling, rounding up, and increased fragmentation. Exog-
enous  treatment with natural  doxSA,  but  not  SA,  also 
induced the observed changes in the mitochondrial phe-
notype, in particular, loss of internal cristae structures, and 
inhibited normal mitochondrial function in situ. Cotreat-
ment  with  doxSA  and  the  CerS  inhibitor  Fumonisin  B1 
(FB1)  fully  rescued  mitotoxicity  caused  by  doxSA  treat-
ment  in  cultured  fibroblasts.  In  adult  sensory  neurons, 
doxSA-induced changes in mitochondrial phenotype pre-
ceded  axonal  degeneration,  arguing  that  mitotoxicity 
could underlie deoxySL-induced neurotoxicity in HSAN1, 
but potentially also in diabetic neuropathy.
MATERIALS AND METHODS
Lipid and chemical probes
The synthesis of alkyne-doxSA is described in detail in the sup-
plemental material to this study and depicted in supplemental 
Fig. S2. Synthesis of (2S,3R)-2-aminooctadec-17-yn-1,3-diol (alkyne-
SA) and alkyne-oleate are published in Refs. 27 and 28, respectively. 
Synthesis  of  azido-sulfo-tetramethyl-BODIPY  (ASTM-BODIPY) 
was published in Ref. 29. The sphingoid base probes d3-doxSA, 
d7-SA,  and  d7-SO  and  the  ceramide  probes  d18:1/12:0  and 
m18:0/12:0 were purchased from Avanti Polar Lipids.
Cell lines and general cell culture procedures
The following cell lines were used in this study: HuH7 (human 
hepatocarcinoma;  JCRB0403),  HepG2  (human  hepatocarci-
noma; ATCC-HB8065), HCT116 (human colorectal  carcinoma; 










Cell culture for LC/MS analysis
MEF  cells  were  cultured  until  70% confluent and then 
treated with 1 µM labeled lipid probes (alkyne-doxSA, d3-doxSA, 
alkyne-SA, or d7-SA)  from ethanolic  stock  solutions. Cells were 
harvested after various incubation times. If needed, the medium 
was collected, lyophilized, and then stored at 20°C until lipid 
extraction. Upon harvesting, cells were first washed with PBS and 
then trypsinized. Cells were counted and washed with PBS, and 
cell pellets were stored at 20°C until lipid extraction.
Analysis of sphingoid and deoxy-sphingoid backbones by 
LC/MS





(10)  as  well  as  with  the  deoxySL  levels  in  the  patients’ 
plasma (11). DoxSA is neurotoxic in vitro (2), and suppres-
sion of doxSA generation by overexpression of the wild-type 
enzyme or by l-serine supplementation prevented the onset 
and improved the clinical signs of the disease in HSAN1 mu-
tant mice  (12,  13).  More  recently,  similar  findings  have 
been reported from an HSAN1 Drosophila model (14). Hence, 
the increased doxSA levels in HSAN1 patients are thought 




elevated  in  patients  suffering  from  metabolic  syndrome 
and  type  2  diabetes  (15–17).  Furthermore,  the  neuro-
pathological  characteristics  of  HSAN1  closely  resemble 










hydroceramides  (doxDHCers)  by  ceramide  synthases 
(CerSs) (19, 20), and desaturated downstream metabolites 





via  sphingosine-1-phosphate  (S1P)  by  S1P  lyase  (25),  al-
though this has never been experimentally addressed.




ids, but this has not been shown yet. Indeed, the study of the 
localization and trafficking of lipids harbors some experi-
mental  challenges. Their  subcellular  localization  is most 
often detected by directly fluorescently labeling the lipids. 
However, the conjugation of a fluorophore can alter the lipid 








similar to its natural counterpart, with the aim of answering 
the following fundamental questions: Can deoxySLs be re-
cycled to canonical sphingolipids or fatty acids? Are there 
major,  so  far  unknown,  downstream doxSA metabolites? 
Where do deoxySLs localize in cells? And can these results 
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the most  abundant  fragment  of  alkyne-doxSA  (alkyne-doxSA  – 
water = 264.26837 Da) is equal to the mass of a sphingosine minus 
two water molecules, whereas the mass of the most abundant al-
kyne-doxSO fragment (alkyne-doxSO – water = 262.25256 Da) is 
equal to the mass of a SA backbone minus two water molecules. 
Therefore,  in  order  to  distinguish  exactly  which  species  arose 
from the alkyne-doxSA,  the  selected  ion chromatogram for  the 
masses of 264.26837 and 262.25256 Da for the alkyne-doxSA-treated 
cells was compared with that of untreated cells and unlabeled 
















alkyne  lipid-containing  medium  was  removed,  and  cells  were 
washed once with growth medium and then further cultured in 
fresh growth medium. Harvested cells were washed once with PBS 





click-reacted  lipids  were  applied  to  TLC  silica  plates  and  sepa-
rated  in  solvent  1  (chloroform/methanol/water/acetic  acid 
65/25/4/1,  two-thirds of  the plate). TLCs were dried and then 
developed in solvent 2 (hexane/ethyl acetate 1/1, whole plate). 
Saturated  versus  desaturated  lipids  such  as  SA/SO,  doxSA/
doxSO, or dihydroceramide (DHCer)/ceramide were not  sepa-
rated from each other by using this TLC method. Directly before 








correction  of  background  fluorescence)  bandpass  emission  fil-





Analysis of subcellular localization of alkyne lipids by 
fluorescence microscopy





prewarmed  100 mM Hepes-KOH,  pH  7.4,  containing  25  nmol 
ASTM-BODIPY, was added per well. The reaction was initiated by 
addition of 20 µl of 100 mM Cu(I)TFB  in acetonitrile, and  the 
pmol  internal  standard  (d7-SA  and d7-SO), was  added  to  each 
sample. Samples were agitated for 1 h at 37°C and centrifuged at 
16,000 g for 5 min to pellet precipitated protein, and the superna-
tant was transferred to a new tube before acid-base hydrolysis was 
performed as described earlier (2, 31).











back  down  to  50%  solvent  A/50%  solvent  B  for  1 min,  and 
column equilibration for 2 min with the same mixture before 
loading of  the next  sample. An atmospheric pressure  chemical 
ionization (APCI) source was used for ionization, and detection 
of  ions was performed  in  full  scan mode by using a Q-Exactive 
hybrid quadrupole Orbitrap mass spectrometer (Thermo, Reinach, 
BL, Switzerland). The detection parameters were as follows: scan 






in XCalibur  (Thermo)  by  integrating  the  area  under  the  peak 
and normalizing to the added internal standards.
Extraction and analysis of ceramides and doxCers  
by LC/MS
Frozen cell pellets were resuspended in 100 µl of PBS. Then, 
666 µl methanol and 333 µl chloroform, including 200 pmol in-
ternal standards (d18:1/12:0; m18:0/12:0), were added. The sam-
ples were then agitated at 1,000 rpm and 37°C for 1 h, followed 
by the addition of 500 µl chloroform and 200 µl alkaline water 
(20 mM  ammonia  in  water).  The  samples  were  centrifuged  at 
16,000 g and the water phase was removed. The organic phase 
was then washed three times with 1 ml of alkaline water. Lipids 









source was used for ionization, and the MS was run in full scan 
and all ion fragmentation modes. All other method parameters 
were the same as for the acid-base hydrolyzed sample method.
Identification of alkyne- and d3-labeled doxDHCer and 
doxCer species
The alkyne and deuterium labeled N-acyl-1-deoxySL-derivatives 
were  identified,  and  the  findings  confirmed,  in  multiple  ways 
(supplemental Fig. S3, supplemental Table S1). Identification was 
performed based on accurate mass (within 5 ppm) of  the non-
fragmented molecular ions, as well as the appropriate fragments, 
including the loss of one water molecule, but not two, and the 
1-deoxysphingoid  base  backbone.  For  the  alkyne-ceramide  spe-
cies,  identification was based on full mass,  the loss of  two water 
molecules, and the labeled sphingoid base backbone. The mass of 
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per well. After attachment, cells were treated for the indicated 
times with lipid and inhibitor from ethanolic stock solutions. The 
assay was performed  in  triplicate measurements  in bicarbonate-
free RPMI medium supplemented with 11 mM glucose, 1 mM py-
ruvate,  and 2 mM glutamine. Three consecutive measurements 
were performed under basal conditions and after the sequential 
addition of 1 µM oligomycin, 2 µM fluoro-carbonyl cyanide phen-
ylhydrazone (FCCP), 1 µM rotenone, and 1 µM antimycin, respec-
tively.  All  reagents  were  purchased  from  Sigma,  except  FCCP, 
which was purchased from Tocris.
Ultrastructural analysis of mitochondria by transmission 
electron microscopy
MEF cells were  seeded onto poly-l-lysine-coated glass bottom 
dishes. After attachment, cells were incubated for 24 h with 1 µM 
doxSA added to the growth medium from an ethanolic stock solu-
tion. Control cells were treated with the same amount of pure 
ethanol  (final  concentration 0.2%). Fixation was performed by 
addition  of  the  fixative  [8%  paraformaldehyde,  5%  glutaralde-




mM sucrose and twice with CB, the samples were contrasted by 
using 1% osmiumtetroxide  in CB on  ice  for 2 h. After washing 
with CB and water, the samples were incubated with 2% uranium 
acetate in water at 4°C for 2 h before final water washes. Sample 
dehydration using ethanol and Epon embedding and polymeriza-




croscope  operated  at  200  kV,  equipped  with  a  TemCam-F416 
camera (TVIPS, Munich, Germany) and using a 20 eV energy fil-
ter slit. The microscope was controlled by the SerialEM software. 
Under  focus  was  adjusted  to  3,000  nm.  Micrographs  were  ac-
quired 2-fold binned. Before tomography data acquisition, areas 
of  interest were preexposed  for at  least 10 min. Tilt  series,  col-
lected over a total angular tilt range from 72° to +72° at 2.0° in-
crements, were first aligned with one another by cross-correlation 




Isolation of mitochondria and analysis of mitochondrial 
membrane potential
MEF cells were grown to 85–95% confluence in 150 × 20 mm 




1 mM EGTA,  pH  7.15)  and  transferred  to  a  Sorvall  centrifuge 
tube. The plate was then washed with another 5 ml cold IB, which 
was  also  transferred  to  the  centrifuge  tube.  Three  plates  were 
pooled together. The cells were then centrifuged for 10 min at 
4°C and 478 g  in an SS-34 rotor (Sorvall, Thermo Fisher Scien-
tific).  The  supernatant  was  removed,  and  the  cell  pellet  was 
retained.
Cell pellets were resuspended in 3.5 ml cold IB and homoge-
nized by 40 strokes with the tight plunger at 1,600 rpm, and the 
homogenate was centrifuged for 3 min at 1,075 g and 4°C. The 
supernatant was collected and spun for 10 min at 11,950 g and 
4°C. Next, the supernatant was decanted, and the inner walls of 





performed according to the manufacturer’s instructions. In brief, 
cells were incubated with 50 nM Mitotracker probe in growth me-
dium for 15 min before cell fixation. For  immunofluorescence, 
antibody staining was performed before submitting the samples 
to the click reaction. The antibodies used in this study were as fol-
lows:  anti-Tom20  (Santa  Cruz,  sc-11415;  1:1,000),  anti-Giantin 
(Abcam 24586; 1:200), anti-protein-disulfide-isomerase (anti-PDI; 
Stressgen SPA891;  1:200),  and  anti-Lamp1  (Abcam ab25245; 
1:1,000). All antibodies were diluted  in 1% cold fish gelantin/ 
0.01% saponin in PBS, except anti-PDI, which was diluted in 1% 
cold  fish  gelantin/0.1%  saponin  in  PBS.  Secondary  antibodies 
were labeled with Alexa 350, Alexa 555, or Alexa 647 (Invitrogen). 
Actin  filaments  were  stained  with  1  µM  Phalloidin-tetramethyl-
rhodamine  isothiocyanate  (Phalloidin-TRITC)  (Sigma  P1951) 
and the cell nuclei with 4’,6-diamidino-2-phenylindole (DAPI).




Quantification of mitochondrial fragmentation in 
fibroblasts





ages of 250 µm × 250 µm were acquired per condition and ran-
domly numbered. In a blinded fashion, cells were counted and 
assigned as either displaying tubular or fragmented mitochondria 
or judged to be close to detachment and cell death.





loney murine  leukemia  virus Reverse Transcriptase  (Promega). 
Qualitative PCR was performed by using primers surrounding the 
XBP1  splicing  site  (5′-ACACGCTTGGGAATGGACAC-3′ and 
5′-CCATGGGAAGATGTTCTGGG-3′).  Products  were  separated 
by a 3% agarose gel electrophoresis and visualized by SYBR-Green 
staining  (Thermo  Fisher  Scientific).  Quantification  was  per-
formed by using the GelPro analyzer software.
Quantification of cellular ATP levels
MEF  cells  were  treated  for  the  indicated  times  with  lipid 





facturers’  instructions. The protein  content was  determined by 
using  Bradford  Reagent  (Sigma-Aldrich).  ATP  levels  were  nor-
malized to protein content.




Analyzer (Seahorse Bioscience). A total of 1 × 104 cells were seeded 
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RESULTS
Uptake, N-acylation, and desaturation of doxSA differs 
greatly from that of the canonical variant SA





















To  verify  the  suitability  of  the  alkyne  probes,  we  first 
compared the uptake, desaturation (supplemental Fig. S5) 
and N-acylation profiles  (Fig. 1) of  alkyne-doxSA and  al-
kyne-SA  with  that  of  their  deuterated  variants  d3-doxSA 
and d7-SA, respectively, in MEFs. Our data showed a com-





that  of  the deuterated ones  (supplemental  Fig.  S5C, D). 
We also analyzed the downstream N-acylation patterns of 
all  probes  after  an  incubation  time of  24 h. Labeled de-
oxySLs were found in substantial quantities as free sphin-
goid bases, doxDHCers, and doxCers (Fig. 1A). We further 
observed  great  differences  in  the  N-acylation  pattern  of 
1-deoxySLs  versus  canonical  sphingolipids.  Whereas  la-
beled doxDHCers were found with a variety of N-acyl fatty 
acids (C16:0-C24:1) attached (Fig. 1B), the majority of la-
beled  doxCers  contained  lignoceric  or  nervonic  acid 
(C24:0 and C24:1) (Fig. 1C).  In contrast,  the majority of 
labeled ceramides were N-acylated  with  palmitic  acid 
(C16:0) (Fig. 1D). Notably, these N-acylation profiles were 
obtained from MEF cells, and, as established for canonical 
sphingolipids, the produced ceramide species will most 
likely depend on the expression levels of the different CerS 
enzymes in the specific cell type under investigation. How-




also  for  the preferred  sphingoid base  substrate. This no-
tion is in concordance with the fact that we observed a re-
duced amount of desaturated metabolites and a slight 
resuspended  in 200 µl of  cold  respiration buffer  (RB;  130 mM 
KCl, 5 mM K2HPO4·3 water, 20 mM MOPS, 2.5 mM EGTA, 3 mM 
succinate, 0.1% BSA, pH 7.15) and spun at 9,500 g for 10 min. The 
supernatant was again decanted, and the mitochondrial pellet was 







lar  Lipids),  SA  (Avanti  Polar Lipids),  and  FB1  (Sigma-Aldrich) 
from  ethanolic  stock  solutions.  Sodium  salicylate  (5  mM)  was 
used as a positive control. Fluorescence values were read every 5 s 
up to 2.5 min.
Analysis of doxSA-mediated toxicity on primary dorsal 
root ganglia neurons
All animal experiments were performed in accordance to the 














robasal-A  medium  supplemented  with  B-27  (Gibco)  and  were 




golipids in ethanol were added 2 h after plating, when neurons 
were already attached to the substrate.
DRG neurons were fixed with 4% paraformaldehyde and 4% 
sucrose.  Cells  were  immunostained  for  Tuj1  (Sigma,  T0198; 
1:1,000) and Tom20 (Santa Cruz, sc-11415; 1:1,000). When neces-
sary,  the  alkyne-moiety  was  subsequently  reacted  with  ASTM-
BODIPY,  as  described  above  for  the  staining  of  fibroblasts. 
Secondary antibodies were labeled with Alexa 350, Alexa 488, or 





lated  by  summarizing  corresponding  pixel  values.  Images  were 
processed by using Fiji software.
Quantification  was  carried  out  for  five  independent  experi-
ments. For quantification of mitochondrial morphology, images 
were randomly taken with an Axiovert microscope (Zeiss). In a 
blinded setup, cells with neurite outgrowth were assigned to dis-
play normal or disturbed mitochondrial morphology. Disturbed 
mitochondrial morphology was assigned for swollen or irregu-
larly distributed mitochondria in at least three neurites. For 
quantification  of  neurite  length,  images  were  randomly  taken 
with an Axiovert microscope (Zeiss) and analyzed by using Im-
ageJ software (NIH). More than 200 neurons for each condition 
were  quantified  for  mitochondrial  morphology  and  neurite 
length, respectively.
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desaturase  and CerSs  seem  to be  sensitive  to  the  slightly 
shorter sphingoid backbone [triple bonds between two car-
bons are 34 pm shorter than single bonds (39)], emphasiz-
ing  the  importance  that  the  structural modification  of  a 
probe should be as minimal as possible.
DeoxySLs are not converted to canonical sphingolipids or 
fatty acids
Canonical sphingolipids can be degraded via S1P by S1P 
lyase (SGPL1)  to  fatty aldehydes and,  consequently,  fatty 
acids. This fact was recapitulated by treatment of MEF cells 
with alkyne-SA  that  resulted  in  the appearance of  the al-
kyne label in ceramides and more complex sphingolipids, 










alkyne-probes  and  detection  by  click-fluorescence  TLC 
provides a good overview of the downstream metabolism 
of  the  respective  lipid. We  therefore  screened  different 





ropathy,  but  also  because  of  the  reported  neurotoxic 
effects of doxSA on CNS neurons in vivo (40–43). We fur-
ther tested liver cell lines (Huh7 and HepG2) because de-




and  the  dermal  barrier  strongly  depends  on  a  well-bal-
anced sphingolipid synthesis. None of the investigated cell 
lines  showed  any  transfer  of  the  alkyne  label  of  alkyne-
doxSA  to  canonical  sphingolipids  or  glycerolipids.  The 
results from human epithelial cells are shown as an exam-
ple (Fig. 2B). In detail, whereas incubation with alkyne-SA 
always  resulted  in  labeling  of  diverse  sphingolipids  and 
glycerolipids, after treatment with alkyne-doxSA, doxDH-
Cer/doxCer  were  the  only  lipids  labeled,  even  after 
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secretion by analyzing the culture medium used during 
the chase.  In addition, we  searched  for cell  type-specific 
doxSA metabolites in the various cell lines (MEF, HCT116, 
A431, HuH7, HepG2, B104, and A172). In some cell lines, 
a minor metabolite  of  alkyne-doxSA  was  detected  run-
ning on the TLCs at the position of SA (Fig. 2D). This in-





Alkyne deoxySLs localize to mitochondria
To  study  the  subcellular  localization of deoxySLs, we 








appreciable amounts. In addition, the detailed analysis of 
pulse-chase  experiments  with  alkyne-doxSA  revealed  a 




periments,  we  observed  no  apparent  cell  toxicity  or  de-
tachment of the cells and excluded a signal loss due to 
Fig. 2.  DeoxySLs are not recycled to canonical sphingolipids or fatty acids. Metabolic tracing of alkyne-doxSA and alkyne-SA by click fluo-
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(1 and 24 h), coinciding with the conversion of alkyne-
doxSA to doxDHCer and doxCer species (Fig. 3D). This 
was  expected,  because  the  enzymes  responsible  for  the 






to  the  exogenous  treatment  with  alkyne-doxSA,  exoge-
nous  treatment  of  cells  with  alkyne-oleate,  a  fatty  acid 
probe  that  is  mostly  incorporated  into  PC  (28),  does 










After  1  h  (Fig.  3B)  and  24  h  of  treatment  (Fig.  3C),  
mitochondrial labeling remained the most prominent, 
whereas  the  intensity  of  the  labeling  increased  over  
time. Apart  from mitochondria,  the alkyne deoxySLs  re-
mained detectable in Golgi and, to a minor degree, were 
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Prolonged incubation with alkyne-doxSA at toxic 




fragmented mitochondria, but also led to changes in al-
kyne-doxSA  localization and  in  the morphology of other 
organelles  in  the  cultured MEF cells.  In detail,  large,  in-
tensely stained structures became visible upon long incuba-
tion with 1 µM alkyne-doxSA (Fig. 6A, white arrows). These 








the majority  of  the  observed  structures  are  enlarged  ER 
domains, as concluded from the overlapping signal of the 
alkyne staining with the ER protein PDI (Fig. 6D, white ar-
row).  These  findings  indicate  that  prolonged  treatment 
with  alkyne-doxSA  at  toxic  concentrations  leads  to mor-
phological changes of the ER, from a net-like appearance 




tein  response  (45). Our data  showed  that XBP1  splicing 
was  significantly  induced  after  24  h  of  exogenous  treat-
ment with doxSA (Fig. 6E).
DoxSA treatment induces mitochondrial dysfunction  
in situ
Hyperfragmentation  of  mitochondria  leads  to  a  re-
duced capacity for ATP production by mitochondrial res-
piration  (46).  We  therefore  hypothesized  that  doxSA 
treatment could lead to a reduction of total cellular ATP 
levels. Indeed, doxSA treatment of MEF cells at toxic con-
centrations  led  to  a  significant  increase  in  cellular  ATP  
after 1 h and a pronounced reduction in cellular ATP lev-
els after 10 and 24 h of treatment (Fig. 7A). This drop in 
cellular  ATP  was,  like  the  mitochondrial  fragmentation 
(Fig. 5C), rescued by cotreatment with 50 µM FB1. Mea-




by cotreatment with FB1, whereas no differences in the 
extracellular acidification rate, as a function of glycolysis, 
were detectable. Ultrastructural analysis of the hyperfrag-
mented mitochondria by electron microscopy showed 
with alkyne-doxSA after fixation did not lead to any ap-
preciable cellular staining (supplemental Fig. S6B).




the detection of the lipid in mitochondria, and the stain-
ing  intensity  increased  with  incubation  time  (Fig. 4A). 
However,  in contrast  to treating cells with a  low alkyne-
doxSA concentration (i.e., 0.1 µM; Fig. 3), treatment of 
MEF cells with 1 µM alkyne-doxSA resulted in changes in 










ger staining of other organelles. Most importantly, we did 
not observe any increase in mitochondrial fragmentation 
upon  treatment  with  alkyne-SA.  To  corroborate  these 
findings and to exclude any potential effect of the alkyne 
moiety,  additional  experiments  using  untagged  natural 
doxSA and SA were performed (Fig. 5). Here, cells were 
treated for the indicated times with 1 µM SA, with in-
creasing concentrations of doxSA (0.1, 0.5, and 1 µM), or 
with  1  µM  doxSA  in  the  presence  of  a  CerS  inhibitor 
(FB1),  respectively.  Cells  were  then  fixed,  stained,  and 
assigned  as  displaying  tubular-shaped  mitochondria, 










tation.  To  further  decipher  this  finding,  we  quantified 




we conclude that an N-acyl downstream product, and not 
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Fig. 6.  Long-term incubation with alkyne-doxSA at toxic concentrations leads to prominent alkyne-positive ER structures and ER stress. MEF 










from mitochondrial hyperfragmentation, doxSA toxicity leads to ER stress. Data are presented as average ± SD. *** P < 0.001. 
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concentrations  (0.5  and  1  µM  doxSA),  but  no  signifi-









Because of  their only  recent  identification  in humans, 
very little is known about effects and functions of deoxySLs 
(49). In this study, we addressed some fundamental ques-
tions about the cellular metabolism and localization of de-
oxySLs,  potentially  leading  to  novel  insights  about  their 
pathomechanism in diseases like diabetic neuropathy and 







suitable  probe  for  the  study  of  deoxySLs  in mammalian 
cells. The  acquired data  also underline  that, whereas  ca-
nonical sphingolipids are mainly desaturated and hence 
rarely present as DHCers, a smaller proportion of deoxySLs 
are desaturated. This notion was  also depicted  in  earlier 
studies that found approximately one-third of the total de-
oxySLs in human plasma to be doxDHCer and two-thirds 
as doxCer  (2).  In  agreement with  a previous  study  (21), 
our results also indicate profound differences in the N-acyl-
ation  pattern  of  doxDHCers  versus  doxCers.  In  detail, 
whereas  in  the  MEF  cells  studied  here,  doxDHCers  are 
found  with  a  variety  of N-acyl  fatty  acids  attached  (C16-





for  canonical  sphingolipids,  CerS  expression  levels  in  a 
given cell will likely affect the specific N-acyl pattern of the 
deoxySLs,  but  the  presence  of  different N-acylation  pat-
terns  between  deoxySLs  and  canonical  ceramides  also 
highly indicates that CerSs may discriminate between their 
sphingoid base substrates. According to the Genevestigator 
database (50), which is based on a large set of quality-con-




and C24:1 fatty acids. Furthermore, CerS2 is also one of the 
most highly expressed CerS enzymes in the DRG of both 
humans  and mice  (along with CerS6  and CerS5,  respec-
tively)  (50),  indicating  that  ceramide  and  dox(DH)Cer 
species found in peripheral nerves are likely be similar to 






were  incubated  with  1  µM  doxSA  and  subsequently  the 
membrane potential depended uptake of the fluorescent 
dye rhodamine (RH-123) (47) was analyzed.
Exogenous doxSA treatment leads to swollen spherical 
mitochondria in primary sensory neurons
Although changes in ER morphology appeared only at 
late  stages  of  doxSA-induced  cellular  toxicity,  when  the 
cell was close to cell death, we observed that the changes 
in mitochondrial morphology, such as swelling, were an 
early characteristic after doxSA treatment and did not per 
se  result  in  cell  death. To  evaluate whether mitotoxicity 
could  be  a  common mechanism  underlying  the  known 
doxSA-induced  neuronal  degeneration,  we  treated  pri-
mary DRG neurons with a mixture of doxSA and alkyne-
doxSA (ratio 1:1) and confirmed uptake and mitochondrial 









we noticed the occurrence of swollen, more spherical, and 
less evenly distributed mitochondria in neurites and accu-
mulation of mitochondria in the cell body already at the 
lowest concentration tested (0.1 µM). This phenotype was 
more pronounced at higher concentrations. Specifically, 
after  treating  neurons  with  0.5  µM  doxSA,  we  observed 
grossly  swollen mitochondria (green arrows) and  irregu-
larly distributed mitochondria (blue arrows) in degenerat-







cell bodies was not  statistically  significant, differences  in 










ogy  (Fig.  8C). Quantification of neurite  length  revealed 
significant differences for treatment with higher doxSA 
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treated for 24 h with 1 M doxSA, 1 M doxSA + 50 M FB1, or 1 M SA, respectively, before analysis of glycolysis rate, mitochondrial res-
piration, and maximal respiration capacity. OCR, oxygen consumption rate. Data are presented as average ± SD. C: MEF cells were treated 
for 24 h with 1 M doxSA, before fixation and analysis of mitochondrial structures by electron microscopy. Scale bars, 200 nm. D: Mitochon-
dria were isolated from MEF cells and incubated in vitro with 1 M doxSA, 1 M doxSA + FB1, or 1 M SA. Uptake of rhodamine 123 was 
analyzed to measure mitochondrial membrane potential. * P < 0.05; ** P < 0.01; *** P < 0.001.
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thors detected swollen, perinuclear mitochondria with en-
larged cristae and a discontinuous outer membrane in 
these cells by electron microscopy. In the present study, we 





mitotoxicity,  indicating  that not  the presence of  the  free 
sphingoid base, but of one of its N-acylated  downstream 






death  (lactate  dehydrogenase  test)  (53).  Here,  reduced 
metabolic activity (MTT test) upon doxSA treatment was 
also rescued in the cortical neurons by preincubation of 
the cells with FB1, again indicating that doxSA needs to be 
N-acylated  to dox(DH)Cers  to affect mitochondrial  func-
tion. In our hands, FB1 cotreatment had no positive effect 




reduced the percentage of peripheral neurons that showed 
disturbed mitochondrial morphology.
Together, our results suggest that elevated deoxySL lev-
els impair mitochondrial function and lead to an energy 
deficit in affected cells, especially in those that highly depend 
on  respiration  for  ATP  production.  Indeed,  peripheral 
nerves have very high and specific energy requirements be-
cause of  the  substantial  length of  the  axons. This makes 
them particularly vulnerable to energy deficits. A chronic 
energy deficit due to mitotoxicity has been proposed as the 
underlying cause for a wide range of distal painful sym-
metrical peripheral neuropathies, including diabetic neu-
ropathy  (54).  Furthermore,  several  inherited  peripheral 
neuropathies are caused by mutations in genes responsible 
for mitochondrial fusion, fission, or transport (55). Specifi-
cally, it is known that mutations in mitofusin 2 (MFN2), a 
protein that controls mitochondrial fusion, cause heredi-
tary motor and  sensory neuropathy Charcot-Marie-Tooth 





assays with single CerSs present in the assay buffer would be 
needed.





are metabolized to only few downstream lipid species, 
when compared with canonical sphingolipids.











toxic  levels  (0.5–1.0  µM  doxSA),  the  majority  of  cells 




ing  to  enlarged  and  highly  visible  perinuclear  ER  struc-










centrations, which are not high enough to induce cell 
death, still resulted in changes in mitochondrial morphol-
ogy. Most  importantly, we  found  that primary DRG neu-
rons displayed changes toward mitochondrial swelling and 
abnormal mitochondrial distribution already at the lowest 
doxSA  concentration  (0.1  µM)  tested.  In  line  with  this, 
changes in mitochondrial morphology have been observed 
before in lymphoblasts from HSAN1 patients that have an 












(D). Data are presented as average ± SD. * P < 0.05; ** P < 0.01; *** P < 0.001. n.s., not significant.
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and  abnormally  clustered mitochondria  (57). Hence,  al-
though  speculative,  a  decreased  mitochondrial  function 
may also be the underlying cause of the neurodegenera-
tion seen in HSAN1. A pathomechanism based on doxSA-
induced  mitotoxicity  could  furthermore  explain  the 
lancinating pain attacks seen in HSAN1. Here, the chronic 
energy  deficit  would  lead  to  inefficient  repolarization  of 
the neuronal membrane and spontaneous discharges that 
are experienced as painful attacks (58).
In conclusion, we have developed and validated a novel 
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